Alicia Gallegos

Librarian finds ‘preposterous number’ of fake references in paper from Springer Nature journal

As a hospital librarian, Jessica Waite is typically successful at tracking down elusive articles for clinicians at Royal Hallamshire Hospital in England. So when a colleague couldn’t locate two references in a paper and asked for help, the librarian grew suspicious.

“These were recent references, which usually we have no problem finding,” Waite told us. “I looked at the issues of the journals where the article should have been, and there were completely different articles, so I immediately thought that the articles we had been asked to find were not real.”

The references were from an article exploring mental health integration after bowel diversion surgery published in Digestive Diseases and Sciences (DDS), a Springer Nature title.

Researcher ‘honestly shocked’ to discover name on paper, editor claims misunderstanding

While reviewing her Google Scholar profile to prepare a list of her publications, psychologist Maryam Farhang came across a paper she didn’t recognize.

The article, in the Journal of Research in Allied Life Sciences, included her name and affiliation, but Farhang hadn’t written or contributed to the paper in any way, she told Retraction Watch.

“I was honestly shocked and very concerned to see my name and affiliation used without my permission,” said Farhang, an associate research professor at Universidad de Las Américas in Chile. “This is not only unethical, but a serious breach of research integrity. As a researcher, authorship comes with responsibility, seeing my name attached to work that I neither wrote nor approved was professionally alarming and personally upsetting.”

Journal retracts GLP-1 study after researcher questions central finding

After reading a recent study about GLP-1 treatment in the International Journal of Obesity, David B. Allison immediately became skeptical about the paper’s analysis. The article, published in May 2024, found people who combined a GLP-1 therapy with another weight loss drug lost more weight than patients on a GLP-1 therapy alone.

“I could not really comprehend exactly what analysis they did,” Allison, chief of nutrition and director of the Children’s Nutrition Research Center at Baylor College of Medicine in Houston, told Retraction Watch. “And more so, I could not comprehend how the analysis they did would give results that would be informative of the conclusions they drew. So I was scratching my head a little bit.”

The IJO paper was a retrospective cohort study of adults with obesity who had been prescribed a GLP-1 therapy, specifically Saxenda and Ozempic. The study compared patients who received a GLP-1 alone with those receiving the GLP-1 therapy and then had bupropion/naltrexone added to their regimen. The Food and Drug Administration approved bupropion/naltrexone in 2014 for chronic weight management in obese adults.

As journal’s retraction count nears 170, it enhances vetting

A journal is implementing tighter controls for guest editors and peer reviewers after an investigation led to the retraction of more than 160 articles.

As we reported last month, the American Society For Testing And Materials (ASTM) International started an investigation into its Journal of Testing and Evaluation after an ASTM vendor noticed some “irregular patterns in the peer review” of a special issue. The investigation revealed the peer review process in four special sections or issues had been compromised, resulting in the retraction of 147 articles.

The journal has since pulled 19 more papers, this time from a special section on human-centered artificial intelligence published in 2021.

Court challenge could chill reporting of research fraud, say whistleblower attorneys

The U.S. government recently announced a record $6.8 billion in False Claims Act settlements and judgments in 2025, the most in a single year since the law’s enactment 163 years ago. For those concerned with scientific integrity, another significant FCA record was also set in 2025: the number of suits brought under the FCA by private individuals against entities they believe defrauded the federal government.

Successful qui tam suits brought under the FCA can come with incentivizing monetary rewards – sometimes substantial – for the whistleblowers. Whistleblowers filed a record 1,297 of these so-called qui tam lawsuits in 2025, up from 979 suits in 2024.

Despite the FCA’s banner year, legal experts say a pending challenge may weaken the law’s whistleblower power and impact. A Florida district court recently struck down the FCA’s qui tam provisions as unconstitutional because these suits involve individuals suing on behalf of the government. If an appeals court upholds the decision, some whistleblowers in that court’s jurisdiction may no longer get paid for exposing wrongdoing, a change that could allow more fraud to slip under the radar, legal analysts say.

U.S. ORI’s first finding of 2026: Researcher faked data in grant apps

A former cancer researcher at University of Oklahoma Health Science Center has been barred from participating in federally funded research without supervision for three years after the U.S. Office of Research Integrity found he falsified data in grant applications.

Daniel Andrade committed research misconduct by falsifying data in two grant applications, according to a summary published Feb. 6 on the ORI website and to be published in the Federal Register. The finding is the agency’s first in 2026 and follows just two findings in 2025.

Now a scientist at Cytovance Biologics, according to LinkedIn, Andrade did not return messages seeking comment. ORI also did not get back to us.

Spanish court rules researcher plagiarized colleague, orders withdrawal of works

Spain’s Supreme Court in Madrid
*Cberbell/Wikimedia Commons*

The Supreme Court of Spain has ordered a literary scholar to pursue retractions of nine works it determined were plagiarized.

The Tribunal Supremo upheld a lower court’s ruling that narrative theory researcher Franciscó Álamo Felices, a professor at the University of Almería in Spain, plagiarized a colleague’s work in two books and seven articles. José R. Valles Calatrava, a literary theory professor at the same university, sued Felices in 2019 for infringement of his intellectual property rights.

That lower court found Felices responsible for “a huge amount of plagiarism at different times and in different articles, revealing a systematic and conscientious parasitic attitude and a desire for appropriation,” according to a translation of the ruling by DeepL Translate. In an October 2025 decision, the Tribunal Supremo dismissed an appeal by Felices against the ruling, finding he failed to demonstrate any fundamental errors of law.

Journal retracts nearly 150 articles for compromised peer review

A journal published by an organization that develops technical standards is retracting 147 papers for problematic peer review — and the publisher expects more to follow.

The American Society For Testing And Materials (ASTM) International started an investigation into its Journal of Testing and Evaluation after an ASTM vendor noticed some “irregular patterns in the peer review” in a special issue, spokesperson Gavin O’Reilly told Retraction Watch. When the publisher confirmed those patterns, ASTM decided to investigate several related issues, he said.

The investigation revealed the peer review process in the special sections or issues had been compromised, each of the retraction notices says.

Lawsuit fails to block retraction of paper claiming to link heart-related deaths to COVID-19 vaccines

*Greg J. Marchand in a photo from his research institute’s website.*

A Taylor & Francis journal has retracted a widely-read paper linking cardiac-related mortality to COVID-19 vaccines after an unsuccessful legal attempt by the lead author to block the withdrawal. That author says he is considering further legal action against the publisher.

The article, “Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies,” drew swift criticism when it was published in Human Vaccines & Immunotherapeutics in August 2023. At the time, critics and sleuths were quick to challenge the data and methods used in the paper, which now has more than 143,000 views on the Taylor & Francis website and has been cited 15 times, including by two letters to the editor of the journal and a response from the authors, according to Clarivate’s Web of Science.

The retraction notice, posted online January 16, states the retraction resulted from concerns that arose about the methodology of the study and the integrity and availability of the data. The authors provided a full response to the queries; however, the publisher determined the validity of the findings remained in question, the notice states. It continues:

Fed up, author issues her own retraction after journal ghosts her

At wit’s end after a publisher ignored her repeated requests for a correction, Ursula Bellut-Staeck took the extreme step of issuing her own retraction. But is that even a thing?

Bellut-Staeck, an independent researcher from Berlin, Germany, submitted a paper to SCIREA Journal of Clinical Medicine last spring after receiving an invitation from the journal. The article, about mechanotransduction and the impact of infrasound and vibrations, was published June 16.

But when Bellut-Staeck realized her affiliation as listed on the article needed changing, she contacted the journal to request a correction. The problem, she said, was linguistic. Because she didn’t realize “affiliation” has a different meaning in German than English, she had mistakenly listed herself as being at an institution she has since left.

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: